Gengraf

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Gengraf

Quick Facts

Property Description
Active Ingredient Cyclosporine (Modified)
Form Oral Capsule and Oral Solution
Pharmacological Class Immunosuppressant (Calcineurin Inhibitor)
Common Use Prevention of organ transplant rejection
Rx Status Prescription Only (Rx)

What is Gengraf and What Class of Medicine is It?

Gengraf is a prescription-only (Rx) medication whose active ingredient is cyclosporine, a drug classified as a potent immunosuppressant. As an immunosuppressant, its primary function is to lower the activity of the body’s natural defense system (the immune system). Gengraf belongs to the class of drugs known as calcineurin inhibitors, a mechanism clinically recognized for its effectiveness in managing transplant patients and certain severe autoimmune conditions.

This confirms that Gengraf is a highly targeted agent used to manage conditions where the immune system needs to be specifically modulated. Gengraf is often used in combination with other agents to suppress the immune system and prevent it from recognizing and attacking a transplanted organ.


The Unique Composition and Purpose of Gengraf

Gengraf is a single-ingredient drug containing a specific, modified formulation of cyclosporine, which has a natural origin. Cyclosporine is a naturally occurring cyclic polypeptide produced as a metabolite by certain fungi. The unique feature of Gengraf is its composition as a microemulsion formulation (or "modified" cyclosporine).

This microemulsion structure ensures the medicine has increased bioavailability and more stable absorption when taken orally compared to the older, non-modified cyclosporine formulations. This crucial feature supports predictable dosing and consistent therapeutic blood levels for the patient. The medicine's overarching purpose is to provide powerful and targeted immune suppression, most commonly to prevent the rejection of transplanted organs such as the kidney, liver, or heart.


What Form Does Gengraf Come In?

Gengraf is available in two forms designed for oral use: a soft gelatin oral capsule and an oral solution (liquid). Both forms contain the active ingredient and are intended to be taken by mouth (oral route of administration) on a consistent schedule. The availability of both a liquid and a solid form offers flexibility, allowing patients to select the form that best meets individual needs for accurate and convenient daily dosing.

Regulatory References

  1. Calcineurin Inhibitors - StatPearls (NIH)

What side effects are possible with Gengraf?

Possible Side Effects and Safety Information

The safety profile of Gengraf (cyclosporine modified) is rigorously defined in official regulatory documents, highlighting risks associated with its role as a potent immunosuppressant. Adverse effects are categorized by frequency and the body system affected, providing a structured view of potential concerns.


Adverse Reaction Classification

Classification Examples of Officially Listed Effects
Very Common (Occurs in ge 1/10) Hypertension (high blood pressure), Nephrotoxicity (changes in kidney function), Tremor, Headache, Hirsutism (excessive hair growth), Hyperlipidemia (high blood fats).
Common (Occurs in ge 1/100 to <1/10) Gastrointestinal issues (nausea, vomiting), Gingival hypertrophy (gum overgrowth), Leukopenia, Anemia, Hyperkalemia (high potassium).

Serious Adverse Reactions

The most serious concerns documented in regulatory labeling relate to the effects of immune suppression, including an increased risk of serious infections and the development of malignancy (specifically lymphomas and skin cancer). Other serious reactions include severe nephrotoxicity (kidney damage), hepatotoxicity (liver damage), and specific neurological disorders like Posterior Reversible Encephalopathy Syndrome (PRES).


Safety Patterns and Constraints

Official documents indicate that the risk and severity of major adverse effects, such as nephrotoxicity and hypertension, are explicitly documented to increase with both higher dosage and longer duration of Gengraf therapy. Due to its narrow therapeutic index, Therapeutic Drug Monitoring (TDM) of blood concentrations is a required safety measure. Specific safety considerations for special populations are noted; for instance, breastfeeding is officially contraindicated because the medicine is excreted into human milk.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Gengraf (cyclosporine modified) overdose is defined by the risk of severe, dose-dependent organ toxicity and the mandated emergency response. Experience with acute, massive overdose is limited; however, manifestations of high drug concentrations are documented.

Officially described signs of toxicity include vomiting, drowsiness, headache, and tachycardia (rapid heart rate). Of greater concern is the potential for severe outcomes, which include acute renal failure (kidney damage) and hepatotoxicity (liver injury). CNS involvement may manifest as seizures or encephalopathy.

Required Emergency Actions

The regulatory guidance mandates immediate medical attention for any suspected overdose scenario. You must contact a poison control center right away or call emergency services if severe symptoms such as loss of consciousness or difficulty breathing occur. Management following an overdose is strictly limited to symptomatic and supportive treatment, as no specific antidote is known for cyclosporine. Hospital monitoring is required, primarily to assess cyclosporine blood concentrations and organ function (e.g., serum creatinine).

Therapeutic Uses of Gengraf

What Gengraf Treats: Main Uses and Benefits

Gengraf (cyclosporine modified) is used in situations involving certain distressing symptoms across multiple therapeutic domains where a moderated immune response is considered relevant for appropriate symptomatic support. Its uses fall into two primary categories that provide supportive relief.


Support for Organ Transplant Protection and Autoimmunity

Gengraf is commonly used across conditions presenting with acute episodes of potential immune-mediated rejection following solid organ transplants, specifically kidney, liver, and heart. It is also applied across domains where additional symptomatic support is needed to help address symptom clusters that may become intense or disruptive in severe, active rheumatoid arthritis and disabling plaque psoriasis. This use is relevant when short-term symptomatic assistance is needed to help manage inflammatory or irritative processes.

“This medication is applied in clinical settings that involve acute or unstable symptom patterns.”

Gengraf contributes to improved comfort during periods of heightened symptoms and provides supportive relief when symptoms interfere with routine activities.


Quick Fact: Support for Inflammatory Symptoms Gengraf supports general well-being during symptomatic phases when inflammatory or irritative symptoms interfere with daily comfort.

Regulatory References

  1. NIH DailyMed Drug Label for Cyclosporine Modified

Eligibility and Restrictions for Use

Who Can and Cannot Use Gengraf?

Gengraf is officially authorized for adults to prevent rejection following solid organ transplants (kidney, liver, or heart). It is also approved for certain severe cases of rheumatoid arthritis and plaque psoriasis in non-immunocompromised adults. Its use for organ transplant is also established in pediatric patients.

Populations for Whom Use is Contraindicated

The medicine must not be used in patients with a known hypersensitivity to cyclosporine or any formulation components. For the treatment of rheumatoid arthritis and psoriasis, Gengraf is contraindicated in patients with:

  • Uncontrolled hypertension
  • Abnormal renal function
  • Malignancies (cancer, excluding certain skin cancers)

Conditional Use and Age Restrictions

  • Organ Function: Patients with renal or severe hepatic impairment require caution and close monitoring of organ function. While impaired renal function is a contraindication for non-transplant use, transplant patients with impaired function require specific dose adjustments and monitoring.
  • Pediatric Use: Safety and effectiveness for the rheumatoid arthritis and psoriasis indications have not been established in the pediatric population.
  • Pregnancy and Lactation: Use during pregnancy is permitted only when the potential benefit outweighs the potential risk. Use in lactating women is not recommended due to the drug being excreted in human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Gengraf (cyclosporine) has documented interactions with numerous medicines and substances, primarily due to its metabolism through the CYP3A4 enzyme system and its effect on the P-glycoprotein transporter. These interactions are classified based on the resulting clinical significance.


Significant Interaction Domains

Interaction Domain Practical Implications (Regulatory Requirement)
CYP3A4 Inhibitors (e.g., Ketoconazole, Verapamil) Increase Gengraf plasma concentrations; requires dose monitoring to prevent toxicity.
CYP3A4 Inducers (e.g., Rifampin, St. John's Wort) Decrease Gengraf plasma concentrations; requires dose adjustment and careful monitoring to avoid loss of efficacy or possible organ rejection.
Nephrotoxic Agents (e.g., NSAIDs, Aminoglycosides) Increase the risk of renal toxicity; requires caution and, in some cases, avoidance of co-administration.
Statins (HMG-CoA Reductase Inhibitors) Specific statins (e.g., Lovastatin, Simvastatin) should be avoided due to the increased risk of myopathy and rhabdomyolysis.

Other Documented Constraints

  • Mycophenolate Mofetil/Sodium: Co-administration decreases the exposure of mycophenolic acid, necessitating close monitoring.
  • Food/Beverages: Avoid or limit consumption of Grapefruit/Grapefruit Juice as they can significantly increase Gengraf levels. Patients must take Gengraf consistently with or without food to maintain uniform absorption and concentrations.
  • Vaccines: The use of live vaccines is generally avoided during Gengraf treatment as the expected protective antibody response may not be obtained, and there is a risk of infection from the vaccine itself.

These official requirements structure the use of Gengraf by establishing necessary monitoring procedures and combination restrictions to manage the risks of toxicity or loss of therapeutic effect.

Mechanism of Action

How Gengraf Works: Mechanism of Action

Gengraf's active ingredient, cyclosporine, exerts its action by entering T-lymphocytes where it binds to the intracellular protein cyclophilin.

This high-affinity binding forms a drug-protein complex that acts as an inhibitor of the enzyme calcineurin (also known as PP3). Inhibition of calcineurin prevents the dephosphorylation and subsequent activation of the transcription factor NF-AT (Nuclear Factor of Activated T-cells).

Since NF-AT cannot enter the nucleus, it cannot initiate the gene transcription required for the synthesis of key immune messengers, particularly interleukin-2 (IL-2). The resulting lack of IL-2 denies T-cells their necessary growth signal, suppressing their ability to multiply and carry out their function. This leads to a systemic dampening of the cellular immune response by limiting T-cell activity and proliferation.

Dosage and Administration Information

The administration of Gengraf (cyclosporine modified) must strictly follow prescribed rules, as the dose is highly individualized and relies on consistent drug levels in the blood.

Official Administration Guidelines

The total daily dose of Gengraf is to be given orally in two equally divided doses (BID), administered approximately 12 hours apart.

Administration Scope Official Instruction
Dosing Schedule Total daily dose is divided into two equal doses, administered every 12 hours.
Timing with Meals The medication must be taken on a consistent schedule regarding meals—always with food or always without food.
Grapefruit Restriction Do not eat grapefruit or drink grapefruit juice while using this medicine.
Monitoring Requirement The dose must be adjusted individually based on the frequent measurement of cyclosporine blood trough concentrations (Therapeutic Drug Monitoring).

Formulation-Specific Instructions

Capsules The capsules must be swallowed whole and must not be crushed, chewed, or opened.

Oral Solution The prescribed amount must be measured using the provided dosing syringe. The solution should be diluted with room-temperature orange or apple juice and mixed in a glass container (do not use plastic). The mixture must be drunk immediately, and the glass should be rinsed with more diluent and consumed to ensure the full dose is received.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Gengraf (Cyclosporine Modified)


Overview of Studies for Organ Transplant Protection

Gengraf was studied to examine acute rejection events and graft survival patterns following the transplant of a kidney, liver, or heart. The evidence base for this application has accumulated over time through clinical use. Randomized Controlled Trials (RCTs) and observational cohort studies have explored outcomes related to graft survival and the frequency of acute rejection episodes. Research examined both newly transplanted individuals and those transitioning from other treatments.

Research has also explored how patients fare when Gengraf is used in combination with other anti-rejection medications, which was observed in the typical clinical scenario. The collective evidence derived from these settings was associated with a High level, consistent with its long-standing role in the overall clinical approach to transplant recipients. Studies report how symptoms evolved in the observed populations regarding patient and organ survival rates.


Research Evidence for Severe Autoimmune Conditions

Gengraf was evaluated in settings involving two specific autoimmune conditions: severe, active rheumatoid arthritis and severe plaque psoriasis. This evidence primarily comes from short- to intermediate-term Randomized Controlled Trials (RCTs).

For severe rheumatoid arthritis, research examined individuals whose disease activity required further investigation following use of other conventional treatments. Studies explored outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level. For severe plaque psoriasis, research monitored the severity and area of skin involvement using assessment tools like the PASI score. In both conditions, findings help contextualize how patients reported their experience during periods of heightened symptom activity.


Key Evidence Gaps and Areas of Uncertainty

Data for certain groups remain insufficient or more limited, such as in pregnant or breastfeeding individuals, or older adults with multiple pre-existing health conditions. Furthermore, the overall evidence quality varies across studies, particularly when comparing results for the autoimmune conditions versus the established use in transplant management.

For both rheumatoid arthritis and psoriasis, the follow-up durations were limited in many controlled trials, and there is limited information for long-term outcomes when the medicine is studied for continuous use beyond one year. In the autoimmune setting, comparative evidence is lacking regarding head-to-head studies with newer biologic treatments.

Key Studies & References

  1. Gengraf (cyclosporine modified) Oral Capsules and Oral Solution Full Prescribing Information
  2. Guideline for the Management of Rheumatoid Arthritis (Example of Major Clinical Guideline)

Frequently Asked Questions (FAQ)

Common questions about Gengraf (FAQ)


Q: Is Gengraf the same as other forms of cyclosporine, like Neoral or Sandimmune, and why does the brand matter?

Gengraf is a modified formulation of the drug cyclosporine, known as a microemulsion. Official information states this design allows for more consistent absorption in the body compared to older, non-modified formulations. The status of cyclosporine as a narrow therapeutic index drug means its blood levels must be strictly controlled. Any change in brand or formulation requires close medical supervision and blood concentration monitoring, as outlined in the official regulatory requirements.


Q: How long does it typically take to see an improvement in symptoms when starting Gengraf for psoriasis or rheumatoid arthritis?

Studies and official product information provide timelines for when improvements may start to appear. For severe rheumatoid arthritis, the onset of action generally occurs between 4 and 8 weeks after starting treatment. Official documentation for severe plaque psoriasis indicates that some patients observed clinical improvement starting as early as 2 weeks.


Q: How often do I need blood tests while on Gengraf to check my drug levels or organ function?

Official information emphasizes the need for frequent monitoring of both cyclosporine blood trough concentrations and kidney and liver function. The specific monitoring schedule, however, is highly personalized and must be established by the prescribing healthcare provider.


Q: What happens if I miss a dose of Gengraf?

Official patient information states that if a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for your next scheduled dose, the missed dose should be skipped, and the patient should return to their regular dosing schedule. It is stated that a patient should not double a dose to compensate for the missed dose.


Q: Why can't Gengraf be mixed with certain liquids or kept in plastic containers?

When preparing the oral solution, instructions require that it be mixed in a glass container using only specific diluents like orange or apple juice. This procedure is required by the label to ensure full dose delivery. The use of plastic or other liquids is discouraged because it can interfere with the drug's properties, potentially causing the medicine to stick to the container.


Q: Why is it important to take Gengraf at the exact same time every day?

It is required to take the drug at the same time every day to maintain a consistent schedule, typically every 12 hours. This strict timing supports the maintenance of stable drug blood levels and predictable absorption, which is important for a narrow therapeutic index drug.


Q: Does Gengraf contain alcohol, and is this a concern for certain patients?

Yes, regulatory documents indicate that Gengraf formulations contain alcohol (ethanol). For example, the oral capsules may contain approximately 12.8% alcohol by volume. This is a point of consideration that patients may wish to discuss with their healthcare provider, especially if they have related health conditions.


Q: Should I tell my doctor if I feel dizzy or confused after taking Gengraf?

Dizziness, confusion, and changes in mental function are listed as documented nervous system side effects of Gengraf. Official information indicates that any new or unusual neurological symptoms should be reported promptly to a healthcare provider, as these effects can sometimes be associated with serious neurological disorders.


Q: Can Gengraf cause numbness or tingling in the hands and feet?

Yes, official safety information lists paresthesia, which is the medical term for abnormal sensations like numbness or tingling, as a documented common side effect of cyclosporine.


Q: If I feel well, is it safe to stop taking Gengraf, or does it need to be tapered off?

Regulatory documents indicate that Gengraf is not intended to be stopped abruptly without the supervision of a physician. For non-transplant indications, the official dosing instructions may include a process for the gradual reduction or tapering off of the medicine if discontinuation is necessary.


Q: Is it okay to drink alcohol in moderation while on Gengraf?

While the regulatory label does not strictly prohibit alcohol consumption, the drug itself contains alcohol. Because Gengraf is metabolized in the liver and can affect the kidneys, combining it with alcohol may increase the risk of liver or kidney toxicity. Questions regarding alcohol consumption should be directed to the prescribing healthcare provider.


Q: Does Gengraf affect fertility or pose risks for future pregnancy?

Official information states that the use of cyclosporine may be associated with impaired fertility in men. For women, its use during pregnancy is permitted only when the benefit is determined to outweigh the risk, and it is contraindicated for use in women who are breastfeeding.


Q: Can Gengraf interact with vaccines, and what is the guidance on vaccinations?

Yes, official warnings state that patients on Gengraf should avoid the use of live, attenuated vaccines. While patients may receive inactivated vaccines, the immunosuppressive effect of Gengraf may diminish the expected protective antibody response from the vaccination.


Q: How long after opening the bottle is the Gengraf oral solution still good to use?

Official storage instructions clearly state that the Gengraf oral solution must be discarded 60 days after the bottle is first opened. This applies regardless of how much of the medicine remains in the bottle.


Q: Is it true that Gengraf helps prevent Graft-versus-Host Disease (GVHD)?

While Gengraf is formally indicated for solid organ transplant rejection, the active ingredient, cyclosporine, has established use in bone marrow transplantation for the prevention of Graft-versus-Host Disease (GVHD). This indicates that the drug's mechanism of action is relevant to preventing this specific complication.


Q: What is the 'modified' characteristic of Gengraf's formula compared to the original cyclosporine?

The 'modified' characteristic refers to its formulation as a microemulsion. This formulation is designed to provide increased bioavailability (better absorption) and more consistent blood levels than the older, non-modified versions of cyclosporine.


Q: Why might a change in my Gengraf brand or formulation be dangerous without a doctor's guidance?

Cyclosporine is a narrow therapeutic index drug. Unauthorized switching can lead to significant changes in drug blood levels, which carry the risk of toxicity or, conversely, may lead to organ rejection or loss of therapeutic effect. Close blood monitoring is required upon any formulation change.


Q: What if the oral solution of Gengraf looks lumpy or appears to have gelled?

Official handling instructions warn that the oral solution must not be refrigerated. If the medicine is stored at temperatures below 68 F (20 C), it may form a gel or sediment. If this happens, it is advised to allow the bottle to warm to room temperature, around 77 F (25 C), before attempting to use it.


Q: Does Gengraf cause acne or other skin changes?

Yes, official safety documents list acne as a possible skin-related side effect. Other documented dermatologic effects include hirsutism, which is the excessive growth of hair.


Q: Does Gengraf cause headaches, and if so, how severe can they be?

Headache is listed in the regulatory documents as a very common adverse effect. Severe or unusual headaches may be a warning sign of a rare but serious neurological condition, such as Posterior Reversible Encephalopathy Syndrome (PRES).


Q: If I have a history of high blood pressure, how does Gengraf affect my condition?

Gengraf frequently causes hypertension (high blood pressure) or can worsen existing high blood pressure. For the treatment of certain autoimmune conditions, the presence of uncontrolled hypertension is a contraindication for using Gengraf. For all patients, blood pressure must be closely monitored and controlled during therapy.


Q: Can Gengraf be used to treat uveitis or other specific autoimmune eye conditions?

While the US label specifies use for transplant rejection, rheumatoid arthritis, and psoriasis, the active ingredient, ciclosporine (modified), is formally indicated in some European regulatory documents for the treatment of endogenous non-infectious uveitis, including Behcet uveitis.


Q: Does Gengraf affect my ability to drive or operate machinery?

The official label lists nervous system side effects such as dizziness, tremor, and confusion. These effects may impair a patient's judgment or physical ability, so caution should be considered when driving or operating machinery.


Q: What is the recommended storage temperature for Gengraf capsules and liquid?

Gengraf must be stored at a controlled room temperature between 59 F and 86 F (15 C to 30 C). The medication must be protected from freezing at all times to maintain its stability and effectiveness.

How should Gengraf be stored and disposed of?

Storage and Disposal Requirements for Gengraf

Gengraf (cyclosporine modified) requires specific environmental controls to maintain stability. The medication must be stored at controlled room temperature, specifically between 59 F and 86 F (15 C to 30 C). It is mandatory to protect the medication from freezing and excessive light and moisture.

Product Form Storage Requirement
Capsules Store in the original, tightly sealed container at room temperature.
Oral Solution Do not refrigerate; discard 60 days after the bottle is first opened.

For safety, Gengraf must be kept out of the reach of children. Unused or expired medication must be properly discarded by consulting a pharmacist or local waste disposal company, as it should not be flushed down the toilet or poured into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Gengraf found in:

A-Z Index: